Abstract
Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Letters in Drug Design & Discovery
Title:Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Volume: 11 Issue: 2
Author(s): Luciana Scotti, Francisco Jaime Bezerra Mendonça Junior, Marcelo Sobral da Silva, Ivan R. Pitta and Marcus Tullius Scotti
Affiliation:
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Abstract: Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Export Options
About this article
Cite this article as:
Scotti Luciana, Jaime Bezerra Mendonça Junior Francisco, Sobral da Silva Marcelo, R. Pitta Ivan and Tullius Scotti Marcus, Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review, Letters in Drug Design & Discovery 2014; 11 (2) . https://dx.doi.org/10.2174/15701808113109990063
DOI https://dx.doi.org/10.2174/15701808113109990063 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NADPH and Iron May Have an Important Role in Attenuated Mucosal Defense in Helicobacter pylori Infection?
Mini-Reviews in Medicinal Chemistry DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Implication of Gut Microbiota in Human Health
CNS & Neurological Disorders - Drug Targets MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis
Current Neuropharmacology Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Extracellular Vesicles as Therapeutics for Brain Injury and Disease
Current Pharmaceutical Design Anti-Phospholipase A2 Receptor Autoantibody: A New Biomarker for Primary Membranous Nephropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Brief but Chronic Increase in Allopregnanolone Cause Accelerated AD Pathology Differently in Two Mouse Models
Current Alzheimer Research Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Current Gene Therapy Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson’s Disease
Medicinal Chemistry Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview
Current Medicinal Chemistry Infectomics in the Discovery and Development of New Antimicrobial Agents
Current Medicinal Chemistry - Anti-Infective Agents Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials
Current Drug Targets The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology